Journal of Infection

Scientists at the University of Cambridge and DIOSynVax have tested an AI-designed universal coronavirus vaccine in a Phase 1 trial involving 39 healthy volunteers, with results published in the Journ…

The University of Cambridge and its spin-out DIOSynVax (DVX) Ltd have completed the first-in-human Phase 1 trial of pEVAC-PS, an AI-designed "universal" Sarbeco coronavirus vaccine. The open-label, do…

A University of Cambridge team and spin-out DIOSynVax reported that a Phase 1 trial of an AI-designed "super-antigen" vaccine was safe and immunogenic in 39 healthy volunteers. The vaccine, whose acti…